The sciatica treatment market size was valued for $678.02 million in 2021 and is estimated to reach $991.26 million by 2031, exhibiting a CAGR of 3.9% from 2022 to 2031.
Sciatica is referred to the pain that mainly affects sciatic nerves whereas sciatic nerves are the nerves that travel from the lower back through the hips and buttocks and down through each leg. Sciatica usually affects only one side of the lower body but the pain can occur in any part of the nerve pathway from the lower back to the buttock and the back of a thigh and calf. Furthermore, common symptoms of sciatica include pain in the leg which may worsen when sitting, burning or tingling down the leg, shooting pain that makes it difficult for the person to stand. Moreover, the pain may also occur in foot and toes, depending on the part of sciatic nerve affected. Sciatica can be treated using various medications or analgesic drugs. The medications include anti-inflammatory drugs, analgesic drugs, anti-convulsant and others.
Major factors that drive the growth of the sciatica treatment market include increase in incidence of sciatica, surge in R&D activities for developing novel therapeutics for sciatica and rise in awareness among the people regarding sciatica and its treatments. There is an increase in incidence of sciatica in the developing and developed countries which have many different causes. Sciatica is mainly caused due to herniated or slipped disk, degenerative disk, spinal stenosis, spondylolisthesis and others. According to the Johns Hopkins Arthritis Center, in the recent population estimates indicate that the prevalence of ankylosing spondylitis (AS) in the U.S. is approximately 0.2-0.5% and based on data from multiple countries, the age- and sex-adjusted incidence of ankylosing spondylitis (AS) is 0.4-14 per 100,000 people.
In addition, in a year about 2% of people get a herniated disk. When a herniated disk happens to a vertebra in lower back, it can press on the sciatic nerve leading to sciatica. Thus, huge prevalence of such conditions leads to increase in incidences of sciatica. This, in turn, propels the growth of the sciatica treatment market.
In addition, increase in R&D activities in pharmaceutical field is driving the growth of the market. Major players are focusing on developing new drugs and APIs having application in sciatica treatment that are potent and efficient. Moreover, there is an increase in outsourcing research activities by the pharmaceutical companies to academic and private contract research organizations (CROs), which allows the company to stay competitive and flexible in a world of increasingly advanced technologies. This supports the key market players to develop novel drug therapies for sciatica and other diseases, which further propels the growth of the market.
Although, various key factors are driving the growth of the market, few factors such as lack of specific approved treatments for sciatica and presence of alternate treatment options hinder the growth of the market. Alternate treatment options including the physiotherapy, and bracing along with surgical treatment restrict the growth of the sciatica treatment market. However, emerging economies of Asia-Pacific and LAMEA present lucrative opportunities for market players for investments. For instance, countries such as China and India with huge population base and high patient pool offer lucrative opportunities for the market growth.
The sciatica treatment market is segmented by type, treatment, distribution channel and region. By type, the market is categorized into acute sciatica, chronic sciatica and others. On the basis of drug class, the market is segregated into non-steroidal anti-inflammatory drug (NSAIDs), steroids, antidepressants, and others. On the basis of distribution channel, the market is categorized into hospital pharmacies, retail and specialty pharmacies and online providers.
Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the Abbott, Alkem Laboratories Limited, Amneal Pharmaceuticals LLC., Aurobindo Pharma, Johnson & Johnson, Sinfonia Biotherapeutics, Sorrento Therapeutics, Inc, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Limited and Zydus Group.
Sciatica is referred to the pain that mainly affects sciatic nerves whereas sciatic nerves are the nerves that travel from the lower back through the hips and buttocks and down through each leg. Sciatica usually affects only one side of the lower body but the pain can occur in any part of the nerve pathway from the lower back to the buttock and the back of a thigh and calf. Furthermore, common symptoms of sciatica include pain in the leg which may worsen when sitting, burning or tingling down the leg, shooting pain that makes it difficult for the person to stand. Moreover, the pain may also occur in foot and toes, depending on the part of sciatic nerve affected. Sciatica can be treated using various medications or analgesic drugs. The medications include anti-inflammatory drugs, analgesic drugs, anti-convulsant and others.
Major factors that drive the growth of the sciatica treatment market include increase in incidence of sciatica, surge in R&D activities for developing novel therapeutics for sciatica and rise in awareness among the people regarding sciatica and its treatments. There is an increase in incidence of sciatica in the developing and developed countries which have many different causes. Sciatica is mainly caused due to herniated or slipped disk, degenerative disk, spinal stenosis, spondylolisthesis and others. According to the Johns Hopkins Arthritis Center, in the recent population estimates indicate that the prevalence of ankylosing spondylitis (AS) in the U.S. is approximately 0.2-0.5% and based on data from multiple countries, the age- and sex-adjusted incidence of ankylosing spondylitis (AS) is 0.4-14 per 100,000 people.
In addition, in a year about 2% of people get a herniated disk. When a herniated disk happens to a vertebra in lower back, it can press on the sciatic nerve leading to sciatica. Thus, huge prevalence of such conditions leads to increase in incidences of sciatica. This, in turn, propels the growth of the sciatica treatment market.
In addition, increase in R&D activities in pharmaceutical field is driving the growth of the market. Major players are focusing on developing new drugs and APIs having application in sciatica treatment that are potent and efficient. Moreover, there is an increase in outsourcing research activities by the pharmaceutical companies to academic and private contract research organizations (CROs), which allows the company to stay competitive and flexible in a world of increasingly advanced technologies. This supports the key market players to develop novel drug therapies for sciatica and other diseases, which further propels the growth of the market.
Although, various key factors are driving the growth of the market, few factors such as lack of specific approved treatments for sciatica and presence of alternate treatment options hinder the growth of the market. Alternate treatment options including the physiotherapy, and bracing along with surgical treatment restrict the growth of the sciatica treatment market. However, emerging economies of Asia-Pacific and LAMEA present lucrative opportunities for market players for investments. For instance, countries such as China and India with huge population base and high patient pool offer lucrative opportunities for the market growth.
The sciatica treatment market is segmented by type, treatment, distribution channel and region. By type, the market is categorized into acute sciatica, chronic sciatica and others. On the basis of drug class, the market is segregated into non-steroidal anti-inflammatory drug (NSAIDs), steroids, antidepressants, and others. On the basis of distribution channel, the market is categorized into hospital pharmacies, retail and specialty pharmacies and online providers.
Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the Abbott, Alkem Laboratories Limited, Amneal Pharmaceuticals LLC., Aurobindo Pharma, Johnson & Johnson, Sinfonia Biotherapeutics, Sorrento Therapeutics, Inc, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Limited and Zydus Group.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the sciatica treatment market analysis from 2021 to 2031 to identify the prevailing sciatica treatment market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's Five Forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the sciatica treatment market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global sciatica treatment market trends, key players, market segments, application areas, and market growth Strategies.
Key Market Segments
By Type
- Acute sciatica
- Chronic sciatica
By Drug class
- Non-steroidal anti-inflammatory drugs
- Steroids
- Antidepressants
By Distribution channel
- Hospital pharmacies
- Retail and specialty pharmacies
- Online providers
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Abbott Laboratories
- Teva Pharmaceutical Industries Limited
- Aurobindo Pharma
- Sorrento Therapeutics, Inc
- Alkem Laboratories Ltd
- Amneal Pharmaceuticals LLC
- Johnson and Johnson
- Sun Pharmaceutical Industries Ltd.
- Sinfonia Biotherapeutics
- Zydus Lifesciences Limited
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. High bargaining power of suppliers
3.3.2. Moderate bargaining power of buyers
3.3.3. Moderate threat of substitutes
3.3.4. Moderate threat of new entrants
3.3.5. Moderate intensity of rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in incidence of sciatica
3.4.1.2. Increase in geriatric population
3.4.1.3. Increase in R&D activities
3.4.2. Restraints
3.4.2.1. Presence of alternate treatment
3.4.3. Opportunities
3.4.3.1. Growth opportunity in emerging markets
3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: SCIATICA TREATMENT MARKET, BY TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Acute sciatica
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Chronic sciatica
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Others
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
CHAPTER 5: SCIATICA TREATMENT MARKET, BY DRUG CLASS
5.1. Overview
5.1.1. Market size and forecast
5.2. Non-steroidal anti-inflammatory drugs
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Steroids
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Antidepressants
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
5.5. Others
5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region
5.5.3. Market share analysis by country
CHAPTER 6: SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospital pharmacies
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Retail and specialty pharmacies
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Online providers
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: SCIATICA TREATMENT MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key trends and opportunities
7.2.2. Market size and forecast, by Type
7.2.3. Market size and forecast, by Drug class
7.2.4. Market size and forecast, by Distribution channel
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Key market trends, growth factors and opportunities
7.2.5.1.2. Market size and forecast, by Type
7.2.5.1.3. Market size and forecast, by Drug class
7.2.5.1.4. Market size and forecast, by Distribution channel
7.2.5.2. Canada
7.2.5.2.1. Key market trends, growth factors and opportunities
7.2.5.2.2. Market size and forecast, by Type
7.2.5.2.3. Market size and forecast, by Drug class
7.2.5.2.4. Market size and forecast, by Distribution channel
7.2.5.3. Mexico
7.2.5.3.1. Key market trends, growth factors and opportunities
7.2.5.3.2. Market size and forecast, by Type
7.2.5.3.3. Market size and forecast, by Drug class
7.2.5.3.4. Market size and forecast, by Distribution channel
7.3. Europe
7.3.1. Key trends and opportunities
7.3.2. Market size and forecast, by Type
7.3.3. Market size and forecast, by Drug class
7.3.4. Market size and forecast, by Distribution channel
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Key market trends, growth factors and opportunities
7.3.5.1.2. Market size and forecast, by Type
7.3.5.1.3. Market size and forecast, by Drug class
7.3.5.1.4. Market size and forecast, by Distribution channel
7.3.5.2. France
7.3.5.2.1. Key market trends, growth factors and opportunities
7.3.5.2.2. Market size and forecast, by Type
7.3.5.2.3. Market size and forecast, by Drug class
7.3.5.2.4. Market size and forecast, by Distribution channel
7.3.5.3. UK
7.3.5.3.1. Key market trends, growth factors and opportunities
7.3.5.3.2. Market size and forecast, by Type
7.3.5.3.3. Market size and forecast, by Drug class
7.3.5.3.4. Market size and forecast, by Distribution channel
7.3.5.4. Italy
7.3.5.4.1. Key market trends, growth factors and opportunities
7.3.5.4.2. Market size and forecast, by Type
7.3.5.4.3. Market size and forecast, by Drug class
7.3.5.4.4. Market size and forecast, by Distribution channel
7.3.5.5. Spain
7.3.5.5.1. Key market trends, growth factors and opportunities
7.3.5.5.2. Market size and forecast, by Type
7.3.5.5.3. Market size and forecast, by Drug class
7.3.5.5.4. Market size and forecast, by Distribution channel
7.3.5.6. Rest of Europe
7.3.5.6.1. Key market trends, growth factors and opportunities
7.3.5.6.2. Market size and forecast, by Type
7.3.5.6.3. Market size and forecast, by Drug class
7.3.5.6.4. Market size and forecast, by Distribution channel
7.4. Asia-Pacific
7.4.1. Key trends and opportunities
7.4.2. Market size and forecast, by Type
7.4.3. Market size and forecast, by Drug class
7.4.4. Market size and forecast, by Distribution channel
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Key market trends, growth factors and opportunities
7.4.5.1.2. Market size and forecast, by Type
7.4.5.1.3. Market size and forecast, by Drug class
7.4.5.1.4. Market size and forecast, by Distribution channel
7.4.5.2. China
7.4.5.2.1. Key market trends, growth factors and opportunities
7.4.5.2.2. Market size and forecast, by Type
7.4.5.2.3. Market size and forecast, by Drug class
7.4.5.2.4. Market size and forecast, by Distribution channel
7.4.5.3. India
7.4.5.3.1. Key market trends, growth factors and opportunities
7.4.5.3.2. Market size and forecast, by Type
7.4.5.3.3. Market size and forecast, by Drug class
7.4.5.3.4. Market size and forecast, by Distribution channel
7.4.5.4. Australia
7.4.5.4.1. Key market trends, growth factors and opportunities
7.4.5.4.2. Market size and forecast, by Type
7.4.5.4.3. Market size and forecast, by Drug class
7.4.5.4.4. Market size and forecast, by Distribution channel
7.4.5.5. South Korea
7.4.5.5.1. Key market trends, growth factors and opportunities
7.4.5.5.2. Market size and forecast, by Type
7.4.5.5.3. Market size and forecast, by Drug class
7.4.5.5.4. Market size and forecast, by Distribution channel
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Key market trends, growth factors and opportunities
7.4.5.6.2. Market size and forecast, by Type
7.4.5.6.3. Market size and forecast, by Drug class
7.4.5.6.4. Market size and forecast, by Distribution channel
7.5. LAMEA
7.5.1. Key trends and opportunities
7.5.2. Market size and forecast, by Type
7.5.3. Market size and forecast, by Drug class
7.5.4. Market size and forecast, by Distribution channel
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Key market trends, growth factors and opportunities
7.5.5.1.2. Market size and forecast, by Type
7.5.5.1.3. Market size and forecast, by Drug class
7.5.5.1.4. Market size and forecast, by Distribution channel
7.5.5.2. Saudi Arabia
7.5.5.2.1. Key market trends, growth factors and opportunities
7.5.5.2.2. Market size and forecast, by Type
7.5.5.2.3. Market size and forecast, by Drug class
7.5.5.2.4. Market size and forecast, by Distribution channel
7.5.5.3. South Africa
7.5.5.3.1. Key market trends, growth factors and opportunities
7.5.5.3.2. Market size and forecast, by Type
7.5.5.3.3. Market size and forecast, by Drug class
7.5.5.3.4. Market size and forecast, by Distribution channel
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Key market trends, growth factors and opportunities
7.5.5.4.2. Market size and forecast, by Type
7.5.5.4.3. Market size and forecast, by Drug class
7.5.5.4.4. Market size and forecast, by Distribution channel
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2021
CHAPTER 9: COMPANY PROFILES
9.1. Abbott Laboratories
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.1.7. Key strategic moves and developments
9.2. Alkem Laboratories Ltd
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.2.7. Key strategic moves and developments
9.3. Amneal Pharmaceuticals LLC
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.4. Johnson and Johnson
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.5. Sinfonia Biotherapeutics
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Key strategic moves and developments
9.6. Sorrento Therapeutics, Inc
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.6.7. Key strategic moves and developments
9.7. Sun Pharmaceutical Industries Ltd.
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.7.7. Key strategic moves and developments
9.8. Zydus Lifesciences Limited
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.9. Teva Pharmaceutical Industries Limited
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.10. Aurobindo Pharma
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance
List of Tables
Table 01. Global Sciatica Treatment Market, by Type, 2021-2031 (Revenue, $Million)
Table 02. Sciatica Treatment Market for Acute Sciatica, by Region, 2021-2031 (Revenue, $Million)
Table 03. Sciatica Treatment Market for Chronic Sciatica, by Region, 2021-2031 (Revenue, $Million)
Table 04. Sciatica Treatment Market for Others, by Region, 2021-2031 (Revenue, $Million)
Table 05. Global Sciatica Treatment Market, by Drug Class, 2021-2031 (Revenue, $Million)
Table 06. Sciatica Treatment Market for Non-Steroidal Anti-Inflammatory Drugs, by Region, 2021-2031 (Revenue, $Million)
Table 07. Sciatica Treatment Market for Steroids, by Region, 2021-2031 (Revenue, $Million)
Table 08. Sciatica Treatment Market for Antidepressants, by Region, 2021-2031 (Revenue, $Million)
Table 09. Sciatica Treatment Market for Others, by Region, 2021-2031 (Revenue, $Million)
Table 10. Global Sciatica Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 11. Sciatica Treatment Market for Hospital Pharmacies, by Region, 2021-2031 (Revenue, $Million)
Table 12. Sciatica Treatment Market for Retail and Specialty Pharmacies, by Region, 2021-2031 (Revenue, $Million)
Table 13. Sciatica Treatment Market for Online Providers, by Region, 2021-2031 (Revenue, $Million)
Table 14. Sciatica Treatment Market, by Region, 2021-2031 (Revenue, $Million)
Table 15. North America Sciatica Treatment Market, by Type, 2021-2031 (Revenue, $Million)
Table 16. North America Sciatica Treatment Market, by Drug Class, 2021-2031 (Revenue, $Million)
Table 17. North America Sciatica Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 18. North America Sciatica Treatment Market, by Country, 2021-2031 (Revenue, $Million)
Table 19. U.S. Sciatica Treatment Market, by Type, 2021-2031 (Revenue, $Million)
Table 20. U.S. Sciatica Treatment Market, by Drug Class, 2021-2031 (Revenue, $Million)
Table 21. U.S. Sciatica Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 22. Canada Sciatica Treatment Market, by Type, 2021-2031 (Revenue, $Million)
Table 23. Canada Sciatica Treatment Market, by Drug Class, 2021-2031 (Revenue, $Million)
Table 24. Canada Sciatica Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 25. Mexico Sciatica Treatment Market, by Type, 2021-2031 (Revenue, $Million)
Table 26. Mexico Sciatica Treatment Market, by Drug Class, 2021-2031 (Revenue, $Million)
Table 27. Mexico Sciatica Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 28. Europe Sciatica Treatment Market, by Type, 2021-2031 (Revenue, $Million)
Table 29. Europe Sciatica Treatment Market, by Drug Class, 2021-2031 (Revenue, $Million)
Table 30. Europe Sciatica Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 31. Europe Sciatica Treatment Market, by Country, 2021-2031 (Revenue, $Million)
Table 32. Germany Sciatica Treatment Market, by Type, 2021-2031 (Revenue, $Million)
Table 33. Germany Sciatica Treatment Market, by Drug Class, 2021-2031 (Revenue, $Million)
Table 34. Germany Sciatica Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 35. France Sciatica Treatment Market, by Type, 2021-2031 (Revenue, $Million)
Table 36. France Sciatica Treatment Market, by Drug Class, 2021-2031 (Revenue, $Million)
Table 37. France Sciatica Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 38. UK Sciatica Treatment Market, by Type, 2021-2031 (Revenue, $Million)
Table 39. UK Sciatica Treatment Market, by Drug Class, 2021-2031 (Revenue, $Million)
Table 40. UK Sciatica Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 41. Italy Sciatica Treatment Market, by Type, 2021-2031 (Revenue, $Million)
Table 42. Italy Sciatica Treatment Market, by Drug Class, 2021-2031 (Revenue, $Million)
Table 43. Italy Sciatica Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 44. Spain Sciatica Treatment Market, by Type, 2021-2031 (Revenue, $Million)
Table 45. Spain Sciatica Treatment Market, by Drug Class, 2021-2031 (Revenue, $Million)
Table 46. Spain Sciatica Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 47. Rest of Europe Sciatica Treatment Market, by Type, 2021-2031 (Revenue, $Million)
Table 48. Rest of Europe Sciatica Treatment Market, by Drug Class, 2021-2031 (Revenue, $Million)
Table 49. Rest of Europe Sciatica Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 50. Asia-Pacific Sciatica Treatment Market, by Type, 2021-2031 (Revenue, $Million)
Table 51. Asia-Pacific Sciatica Treatment Market, by Drug Class, 2021-2031 (Revenue, $Million)
Table 52. Asia-Pacific Sciatica Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 53. Asia-Pacific Sciatica Treatment Market, by Country, 2021-2031 (Revenue, $Million)
Table 54. Japan Sciatica Treatment Market, by Type, 2021-2031 (Revenue, $Million)
Table 55. Japan Sciatica Treatment Market, by Drug Class, 2021-2031 (Revenue, $Million)
Table 56. Japan Sciatica Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 57. China Sciatica Treatment Market, by Type, 2021-2031 (Revenue, $Million)
Table 58. China Sciatica Treatment Market, by Drug Class, 2021-2031 (Revenue, $Million)
Table 59. China Sciatica Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 60. India Sciatica Treatment Market, by Type, 2021-2031 (Revenue, $Million)
Table 61. India Sciatica Treatment Market, by Drug Class, 2021-2031 (Revenue, $Million)
Table 62. India Sciatica Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 63. Australia Sciatica Treatment Market, by Type, 2021-2031 (Revenue, $Million)
Table 64. Australia Sciatica Treatment Market, by Drug Class, 2021-2031 (Revenue, $Million)
Table 65. Australia Sciatica Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 66. South Korea Sciatica Treatment Market, by Type, 2021-2031 (Revenue, $Million)
Table 67. South Korea Sciatica Treatment Market, by Drug Class, 2021-2031 (Revenue, $Million)
Table 68. South Korea Sciatica Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 69. Rest of Asia-Pacific Sciatica Treatment Market, by Type, 2021-2031 (Revenue, $Million)
Table 70. Rest of Asia-Pacific Sciatica Treatment Market, by Drug Class, 2021-2031 (Revenue, $Million)
Table 71. Rest of Asia-Pacific Sciatica Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 72. LAMEA Sciatica Treatment Market, by Type, 2021-2031 (Revenue, $Million)
Table 73. LAMEA Sciatica Treatment Market, by Drug Class, 2021-2031 (Revenue, $Million)
Table 74. LAMEA Sciatica Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 75. LAMEA Sciatica Treatment Market, by Country, 2021-2031 (Revenue, $Million)
Table 76. Brazil Sciatica Treatment Market, by Type, 2021-2031 (Revenue, $Million)
Table 77. Brazil Sciatica Treatment Market, by Drug Class, 2021-2031 (Revenue, $Million)
Table 78. Brazil Sciatica Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 79. Saudi Arabia Sciatica Treatment Market, by Type, 2021-2031 (Revenue, $Million)
Table 80. Saudi Arabia Sciatica Treatment Market, by Drug Class, 2021-2031 (Revenue, $Million)
Table 81. Saudi Arabia Sciatica Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 82. South Africa Sciatica Treatment Market, by Type, 2021-2031 (Revenue, $Million)
Table 83. South Africa Sciatica Treatment Market, by Drug Class, 2021-2031 (Revenue, $Million)
Table 84. South Africa Sciatica Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 85. Rest of LAMEA Sciatica Treatment Market, by Type, 2021-2031 (Revenue, $Million)
Table 86. Rest of LAMEA Sciatica Treatment Market, by Drug Class, 2021-2031 (Revenue, $Million)
Table 87. Rest of LAMEA Sciatica Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 88. Abbott Laboratories: Key Executives
Table 89. Abbott Laboratories: Company Snapshot
Table 90. Abbott Laboratories: Product Segments
Table 91. Abbott Laboratories: Product Portfolio
Table 92. Abbott Laboratories: Key Strategies
Table 93. Alkem Laboratories Ltd.: Key Executives
Table 94. Alkem Laboratories Ltd.: Company Snapshot
Table 95. Alkem Laboratories Ltd.: Product Segments
Table 96. Alkem Laboratories Ltd.: Product Portfolio
Table 97. Alkem Laboratories Ltd.: Key Strategies
Table 98. Amneal Pharmaceuticals LLC: Key Executives
Table 99. Amneal Pharmaceuticals LLC: Company Snapshot
Table 100. Amneal Pharmaceuticals LLC: Product Segments
Table 101. Amneal Pharmaceuticals LLC: Product Portfolio
Table 102. Johnson and Johnson: Key Executives
Table 103. Johnson and Johnson: Company Snapshot
Table 104. Johnson and Johnson: Product Segments
Table 105. Johnson and Johnson: Product Portfolio
Table 106. Sinfonia Biotherapeutics: Key Executives
Table 107. Sinfonia Biotherapeutics: Company Snapshot
Table 108. Sinfonia Biotherapeutics: Product Segments
Table 109. Sinfonia Biotherapeutics: Product Portfolio
Table 110. Sinfonia Biotherapeutics: Key Strategies
Table 111. Sorrento Therapeutics, Inc.: Key Executives
Table 112. Sorrento Therapeutics, Inc.: Company Snapshot
Table 113. Sorrento Therapeutics, Inc.: Product Segments
Table 114. Sorrento Therapeutics, Inc.: Product Portfolio
Table 115. Sorrento Therapeutics, Inc.: Key Strategies
Table 116. Sun Pharmaceutical Industries Ltd.: Key Executives
Table 117. Sun Pharmaceutical Industries Ltd.: Company Snapshot
Table 118. Sun Pharmaceutical Industries Ltd.: Product Segments
Table 119. Sun Pharmaceutical Industries Ltd.: Product Portfolio
Table 120. Sun Pharmaceutical Industries Ltd.: Key Strategies
Table 121. Zydus Lifesciences Limited: Key Executives
Table 122. Zydus Lifesciences Limited: Company Snapshot
Table 123. Zydus Lifesciences Limited: Product Segments
Table 124. Zydus Lifesciences Limited: Product Portfolio
Table 125. Teva Pharmaceutical Industries Limited: Key Executives
Table 126. Teva Pharmaceutical Industries Limited: Company Snapshot
Table 127. Teva Pharmaceutical Industries Limited: Product Segments
Table 128. Teva Pharmaceutical Industries Limited: Product Portfolio
Table 129. Aurobindo Pharma: Key Executives
Table 130. Aurobindo Pharma: Company Snapshot
Table 131. Aurobindo Pharma: Product Segments
Table 132. Aurobindo Pharma: Product Portfolio
List of Figures
Figure 01. Sciatica Treatment Market, 2021-2031
Figure 02. Segmentation of Sciatica Treatment Market, 2021-2031
Figure 03. Top Investment Pockets in Sciatica Treatment Market (2022-2031)
Figure 04. High Bargaining Power of Suppliers
Figure 05. Moderate Bargaining Power of Buyers
Figure 06. Moderate Threat of Substitutes
Figure 07. Moderate Threat of New Entrants
Figure 08. Moderate Intensity of Rivalry
Figure 09. Drivers, Restraints and Opportunities: Globalsciatica Treatment Market
Figure 10. Sciatica Treatment Market, by Type, 2021(%)
Figure 11. Comparative Share Analysis of Sciatica Treatment Market for Acute Sciatica, by Country 2021-2031(%)
Figure 12. Comparative Share Analysis of Sciatica Treatment Market for Chronic Sciatica, by Country 2021-2031(%)
Figure 13. Comparative Share Analysis of Sciatica Treatment Market for Others, by Country 2021-2031(%)
Figure 14. Sciatica Treatment Market, by Drug Class, 2021(%)
Figure 15. Comparative Share Analysis of Sciatica Treatment Market for Non-Steroidal Anti-Inflammatory Drugs, by Country 2021-2031(%)
Figure 16. Comparative Share Analysis of Sciatica Treatment Market for Steroids, by Country 2021-2031(%)
Figure 17. Comparative Share Analysis of Sciatica Treatment Market for Antidepressants, by Country 2021-2031(%)
Figure 18. Comparative Share Analysis of Sciatica Treatment Market for Others, by Country 2021-2031(%)
Figure 19. Sciatica Treatment Market, by Distribution Channel, 2021(%)
Figure 20. Comparative Share Analysis of Sciatica Treatment Market for Hospital Pharmacies, by Country 2021-2031(%)
Figure 21. Comparative Share Analysis of Sciatica Treatment Market for Retail and Specialty Pharmacies, by Country 2021-2031(%)
Figure 22. Comparative Share Analysis of Sciatica Treatment Market for Online Providers, by Country 2021-2031(%)
Figure 23. Sciatica Treatment Market by Region, 2021
Figure 24. U.S. Sciatica Treatment Market, 2021-2031 ($Million)
Figure 25. Canada Sciatica Treatment Market, 2021-2031 ($Million)
Figure 26. Mexico Sciatica Treatment Market, 2021-2031 ($Million)
Figure 27. Germany Sciatica Treatment Market, 2021-2031 ($Million)
Figure 28. France Sciatica Treatment Market, 2021-2031 ($Million)
Figure 29. UK Sciatica Treatment Market, 2021-2031 ($Million)
Figure 30. Italy Sciatica Treatment Market, 2021-2031 ($Million)
Figure 31. Spain Sciatica Treatment Market, 2021-2031 ($Million)
Figure 32. Rest of Europe Sciatica Treatment Market, 2021-2031 ($Million)
Figure 33. Japan Sciatica Treatment Market, 2021-2031 ($Million)
Figure 34. China Sciatica Treatment Market, 2021-2031 ($Million)
Figure 35. India Sciatica Treatment Market, 2021-2031 ($Million)
Figure 36. Australia Sciatica Treatment Market, 2021-2031 ($Million)
Figure 37. South Korea Sciatica Treatment Market, 2021-2031 ($Million)
Figure 38. Rest of Asia-Pacific Sciatica Treatment Market, 2021-2031 ($Million)
Figure 39. Brazil Sciatica Treatment Market, 2021-2031 ($Million)
Figure 40. Saudi Arabia Sciatica Treatment Market, 2021-2031 ($Million)
Figure 41. South Africa Sciatica Treatment Market, 2021-2031 ($Million)
Figure 42. Rest of LAMEA Sciatica Treatment Market, 2021-2031 ($Million)
Figure 43. Top Winning Strategies, by Year
Figure 44. Top Winning Strategies, by Development
Figure 45. Top Winning Strategies, by Company
Figure 46. Product Mapping of Top 10 Players
Figure 47. Competitive Dashboard
Figure 48. Competitive Heatmap: Sciatica Treatment Market
Figure 49. Top Player Positioning, 2021
Figure 50. Abbott Laboratories: Net Sales, 2019-2021 ($Million)
Figure 51. Abbott Laboratories: Revenue Share by Segment, 2021 (%)
Figure 52. Abbott Laboratories: Revenue Share by Region, 2021 (%)
Figure 53. Alkem Laboratories Ltd.: Net Revenue, 2019-2021 ($Million)
Figure 54. Alkem Laboratories Ltd.: Revenue Share by Region, 2021 (%)
Figure 55. Amneal Pharmaceuticals LLC: Net Revenue, 2019-2021 ($Million)
Figure 56. Amneal Pharmaceuticals LLC: Revenue Share by Segment, 2021 (%)
Figure 57. Johnson and Johnson: Sales Revenue, 2019-2021 ($Million)
Figure 58. Johnson and Johnson: Revenue Share by Segment, 2021 (%)
Figure 59. Johnson and Johnson: Revenue Share by Region, 2021 (%)
Figure 60. Sorrento Therapeutics, Inc.: Net Revenue, 2019-2021 ($Million)
Figure 61. Sorrento Therapeutics, Inc.: Revenue Share by Segment, 2021 (%)
Figure 62. Sun Pharmaceutical Industries Ltd.: Net Revenue, 2019-2021 ($Million)
Figure 63. Sun Pharmaceutical Industries Ltd.: Revenue Share by Region, 2021 (%)
Figure 64. Zydus Lifesciences Limited: Net Revenue, 2019-2021 ($Million)
Figure 65. Zydus Lifesciences Limited: Revenue Share by Segment, 2021 (%)
Figure 66. Zydus Lifesciences Limited: Revenue Share by Region, 2021 (%)
Figure 67. Teva Pharmaceutical Industries Limited: Net Revenue, 2019-2021 ($Million)
Figure 68. Teva Pharmaceutical Industries Limited: Revenue Share by Segment, 2021 (%)
Figure 69. Aurobindo Pharma: Net Revenue, 2019-2021 ($Million)
Figure 70. Aurobindo Pharma: Revenue Share by Region, 2021 (%)
Executive Summary
According to the report titled, 'Sciatica Treatment Market,' the sciatica treatment market size was valued at $678.02 million in 2021, and is estimated to reach $991.3 million by 2031, growing at a CAGR of 3.9% from 2022 to 2031.Sciatica is referred to the condition in which the lower part of the body experiences discomfort when there is a sciatic nerve is damaged. The sciatic nerve is the largest nerve in the human body which gets compressed as a result of various conditions such as lumbar disc herniation and spinal stenosis. Sciatica pain radiates from the lumbar region of the body to the back of the thigh and may also extend below the knee. There are several medications in the market such as analgesic, anti-depressants, anti-convulsant and others that are used for the treatment of sciatica.
Key factors driving the growth of the sciatica treatment market include rise in incidence of sciatica, increase in geriatric population and increase in R&D activities. In addition, increase in demand for NSIADs for sciatica treatment is driving the growth of the market. NSAIDs are widely used for the management of pain and inflammation associated with sciatica and lower back pain, and its growing popularity is driving demand for these drugs. The key players in the market are also investing on a large scale for increasing the production of NSAIDs as well as in the development of new and advanced treatments. This investment is aimed at meeting the growing demand for effective and efficient sciatica treatment options, as well as at expanding the company's market share and strengthening its position in the industry. In addition, availability of medication in various advanced types of formulations is leading to the increase in adoption of NSIADs in sciatica treatment, thereby propelling the market growth.
Furthermore, as the global population ages, the number of people suffering from sciatica and lower back pain is increasing, which is driving demand for treatment options and propelling the growth of sciatica treatment market. Also, increasing disposable incomes and better access to healthcare, allows people are more likely to seek medical treatment for sciatica symptoms. In addition, increasing awareness of sciatica and its symptoms, as well as the availability of better diagnostic and treatment options, is also driving growth in the sciatica treatment market.
Furthermore, high unmet needs and emerging new markets is anticipated to offer lucrative opportunity for the growth of the market. As population is increasing rapidly allover, there is also increase in demand for diagnosis and treatment services around the globe. in addition, prevalence of unmet medical needs in underdeveloped as well as developing countries is anticipated to drive the market during the forecast period. On the other hand, to over this situation, there is an increase in investments by the key market players in emerging countries which offer lucrative opportunity for the growth of the market in the future.
The global sciatica treatment market is segmented by type, treatment, distribution channel and region. By type, the market is categorized into acute sciatica, chronic sciatica and others. On the basis of drug class, the market is segregated into non-steroidal anti-inflammatory drug (NSAIDs), steroids, antidepressants, and others. On the basis of distribution channel, the market is categorized into hospital pharmacies, retail and specialty pharmacies and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
The key players profiled in the study include Abbott, Alkem Laboratories Limited, Amneal Pharmaceuticals LLC., Aurobindo Pharma, Johnson and Johnson, Sinfonia Biotherapeutics, Sorrento Therapeutics, Inc, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Limited and Zydus Group. The players in the market have been actively engaged in the adoption various Strategies such as product launch, product development, geographical expansion, clinical trials and others to remain competitive and gain advantage over the competitors in the market. For instance, in August 2021, Alkem Laboratories Ltd. announced the launch of Ibuprofen and Famotidine Tablets in the U.S., following an approval from the U.S. Food and Drug Administration (US FDA).
Key Market Insights
- By type, the chronic sciatica segment was the highest revenue contributor to the market in 2021 and is estimated to reach $777.52 million by 2031, with a CAGR of 4.0% and is estimated to be the fastest-growing segment during the forecast period.
- By drug class, the non-steroidal anti-inflammatory drugs segment dominated the global market and is expected to be the fastest-growing segment during the forecast period.
- Based on distribution channel, the retail and specialty pharmacies segment was the highest revenue contributor to the market in 2021, and online providers segment is anticipated to grow at a fastest rate during the forecast period.
- Based on region, North America garnered the largest revenue share in 2021, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.
Companies Mentioned
- Abbott Laboratories
- Teva Pharmaceutical Industries Limited
- Aurobindo Pharma
- Sorrento Therapeutics, Inc
- Alkem Laboratories Ltd
- Amneal Pharmaceuticals LLC
- Johnson and Johnson
- Sun Pharmaceutical Industries Ltd.
- Sinfonia Biotherapeutics
- Zydus Lifesciences Limited
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
